Literature DB >> 12356575

Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis.

John A Belperio1, Maria Dy, Marie D Burdick, Ying Y Xue, Kewang Li, Jack A Elias, Michael P Keane.   

Abstract

The initial stimulus for inflammatory cell recruitment and the mechanisms responsible for the perpetuation and evolution of chronic inflammation, granulation tissue formation, and fibrosis have not been fully elucidated. Although interleukin (IL)-13, a Th2 cytokine, has been shown to have direct effects on fibroblasts that support fibroproliferation, it is also a potent inducer of a novel CC chemokine, C10, which is chemotactic for mononuclear phagocytes. The macrophage/mononuclear phagocyte has been shown to have a role in the pathogenesis of pulmonary fibrosis, serving as an important source of growth factors that regulate extracellular matrix synthesis. In this study we demonstrate that IL-13 and C10 are elevated in the pathogenesis of bleomycin-induced pulmonary fibrosis. Neutralization of IL-13, but not IL-4, attenuated bleomycin-induced pulmonary fibrosis and levels of C10, suggesting that IL-13 has an important role in the development of pulmonary fibrosis. IL-13 is a potent inducer of C10 in vivo, and neutralization of C10 attenuated bleomycin-induced pulmonary fibrosis and intrapulmonary macrophage numbers. This suggests that IL-13 has a role in the development of pulmonary fibrosis that is independent of its direct effect on fibroblasts and is evidence for an interaction between Th2 cytokines and specific CC chemokines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12356575     DOI: 10.1165/rcmb.2002-0009OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  83 in total

1.  Repetitive intradermal bleomycin injections evoke T-helper cell 2 cytokine-driven pulmonary fibrosis.

Authors:  Brijendra Singh; Rajesh K Kasam; Vishwaraj Sontake; Thomas A Wynn; Satish K Madala
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-03       Impact factor: 5.464

Review 2.  Fibrotic disease and the T(H)1/T(H)2 paradigm.

Authors:  Thomas A Wynn
Journal:  Nat Rev Immunol       Date:  2004-08       Impact factor: 53.106

Review 3.  Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models.

Authors:  Yukio Takeshita; Richard M Ransohoff
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

4.  CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury.

Authors:  Bethany B Moore; Jill E Kolodsick; Victor J Thannickal; Kenneth Cooke; Thomas A Moore; Cory Hogaboam; Carol A Wilke; Galen B Toews
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

5.  Characterization of Quin-C1 for its anti-inflammatory property in a mouse model of bleomycin-induced lung injury.

Authors:  Min He; Ni Cheng; Wei-wei Gao; Meng Zhang; Yue-yun Zhang; Richard D Ye; Ming-wei Wang
Journal:  Acta Pharmacol Sin       Date:  2011-04-18       Impact factor: 6.150

Review 6.  Transgenic modeling of transforming growth factor-beta(1): role of apoptosis in fibrosis and alveolar remodeling.

Authors:  Chun Geun Lee; Hye-Ryun Kang; Robert J Homer; Geoffrey Chupp; Jack A Elias
Journal:  Proc Am Thorac Soc       Date:  2006-07

7.  Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.

Authors:  Lynne A Murray; Huilan Zhang; Sameer R Oak; Ana Lucia Coelho; Athula Herath; Kevin R Flaherty; Joyce Lee; Matt Bell; Darryl A Knight; Fernando J Martinez; Matthew A Sleeman; Erica L Herzog; Cory M Hogaboam
Journal:  Am J Respir Cell Mol Biol       Date:  2014-05       Impact factor: 6.914

8.  Genetic susceptibility to interstitial pulmonary fibrosis in mice induced by vanadium pentoxide (V2O5).

Authors:  Dianne M Walters; Kevin M White; Ushma Patel; Martin J Davis; Roberta M Veluci-Marlow; Solomon Raju Bhupanapadu Sunkesula; James C Bonner; Jessica R Martin; Wes Gladwell; Steven R Kleeberger
Journal:  FASEB J       Date:  2013-11-27       Impact factor: 5.191

Review 9.  Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.

Authors:  Karen Au; Dinesh Khanna; Philip J Clements; Daniel E Furst; Donald P Tashkin
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

10.  Interleukin-13 and its receptors in idiopathic interstitial pneumonia: clinical implications for lung function.

Authors:  Sung-Woo Park; Mi-Hyun Ahn; Hee Kyung Jang; An Soo Jang; Do-Jin Kim; Eun-Suk Koh; Jong-Sook Park; Soo-Taek Uh; Yong Hoon Kim; Jai Soung Park; Sang Hyun Paik; Hwa-Kyun Shin; Wook Youm; Choon-Sik Park
Journal:  J Korean Med Sci       Date:  2009-07-29       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.